Tamper resistant dosage forms

Patent metadata

Field	Value
Publication number	US-9492393-B2
Application number	US-201514729660-A
Country	US
Kind code	B2
Filing date	Jun 3, 2015
Priority date	Aug 25, 2006
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

First claim

The invention claimed is:

1. A method of treating pain comprising administering to a patient in need thereof a pharmaceutical tablet comprising:
(1) at least a first compression shaped and then air cured matrix, wherein said curing is without compression by heated air having a temperature of at least about 62° C. for a duration of at least about 5 minutes, said matrix comprising oxycodone or a pharmaceutically acceptable salt thereof in combination with at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight selected from the group consisting of 4,000,000, 7,000,000, and a combination thereof, and optionally further comprising at least one low molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000;
(2) optionally a second air cured matrix comprising oxycodone or a pharmaceutically acceptable salt thereof in combination with at least one low molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000; and
(3) optionally a coating,

wherein in said tablet:
(i) said oxycodone or pharmaceutically acceptable salt thereof is provided in a dose selected from the group consisting of 10 mg, 15, mg, 20 mg, and 30 mg;
the total combined weight of said low molecular weight polyethylene oxide, if present, and said high molecular weight polyethylene oxide is at least 79% by weight of the total weight of said tablet, excluding the weight of any coatings; and
said low molecular weight polyethylene oxide, if present, is at least 10% by weight of the total weight of said uncoated tablet, excluding the weight of any coatings; or
(ii) said oxycodone or pharmaceutically acceptable salt thereof is provided in a dose selected from the group consisting of 40 mg, 60 mg, and 80 mg;
the total combined weight of said low molecular weight polyethylene oxide, if present, and said high molecular weight polyethylene oxide is at least 65% by weight of the total weight of said tablet, excluding the weight of any coatings; and
said low molecular weight polyethylene oxide, if present, is at least 10% by weight of the total weight of said tablet, excluding the weight of any coatings; and
said tablet provides a dosage form for twice-daily extended release administration of oxycodone or pharmaceutically acceptable salt thereof.

2. A method as defined in claim 1 , wherein said oxycodone or pharmaceutical salt thereof comprises at least 5% by weight, based upon the total weight of said uncoated tablet.

3. A method as defined in claim 1 , wherein each shaped and cured matrix has been cured by heated air having a temperature of about 62° C. to about 90° C. for a duration of about 15 minutes to about 10 hours, and then is subsequently cooled.

4. A method as defined in claim 3 , wherein said heated air temperature is from about 65° C. to about 90° C., said duration is about 15 minutes to about 8 hours, and said cooling comprises exposure to an air temperature of less than about 62° C.

5. A method as defined in claim 1 , wherein said shaped tablet is coated at least one of before or after being cured.

6. A method as defined in claim 4 , wherein one or both of said first matrix and second matrix further comprise a coating.

7. A method as defined in claim 1 , wherein, said second matrix is not present, the dosage amount of oxycodone is selected from 10 mg, 15, mg, 20 mg, and 30 mg, and the total combined weight of said high and low molecular weight polyethylene oxide is at least 79% by weight of the total weight of said uncoated tablet.

8. A method as defined in claim 1 , wherein, said second matrix is not present, the dosage amount of oxycodone is selected from 40 mg, 60 mg, and 80 mg, and the total combined weight of said high and low molecular weight polyethylene oxide is at least 65% by weight of the total weight of said uncoated tablet.

9. A method as defined in claim 7 , wherein said low molecular weight polyethylene oxide is not present.

10. A method as defined in claim 8 , wherein said low molecular weight polyethylene oxide is not present.

11. A method as defined in claim 5 , wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 65% by weight, based upon the total weight of said uncoated tablet.

12. A method as defined in claim 5 , wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 80% by weight, based upon the total weight of said uncoated tablet.

13. A method as defined in claim 5 , wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 85% by weight, based upon the total weight of said uncoated tablet.

14. A method as defined in claim 5 , wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 90% by weight, based upon the total weight of said uncoated tablet.

15. A method as defined in claim 5 , wherein said tablet further comprises magnesium stearate.

16. A method as defined in claim 15 , wherein said tablet further comprises butylated hydroxytoluene.

17. A method as defined in claim 15 , wherein said tablet further comprises at least one of lactose, microcrystalline cellulose and hydroxypropyl cellulose.

18. A method as defined in claim 1 , wherein said tablet, when subjected to an indentation test, has at least one of (i) a cracking force of at least 110 N; and (ii) a penetration depth to crack distance of at least 1.0 mm.

19. A method as defined in claim 1 , wherein said tablet can be flattened to a thickness that is no more than about 60% of the initial tablet thickness without breaking; and said flattened tablet swells upon exposure to water or ethanol.

20. A method according to claim 1 , wherein, after a plurality of at least 100 of the same tablets are stored at 40° C. and 75% relative humidity for at least 3months, a set of at least ten of said stored tablets, on average, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C., in the absence of an added stabilizer, release an amount of said oxycodone or pharmaceutical salt thereof, after 1 hour, 4 hours, and 12 hours, that deviates from an initial dosage amount of said oxycodone or pharmaceutical salt thereof by no more than about 10% points.

21. A method as defined in claim 3 , wherein said air temperature during curing exhibits a plateau profile.

22. A method as defined in claim 4 , wherein said air temperature during curing exhibits a plateau profile.

23. A method as defined in claim 3 , wherein said air temperature during curing exhibits a parabolic or triangular profile.

24. A method as defined in claim 4 , wherein said air temperature during curing exhibits a parabolic or triangular profile.

25. A method as defined in claim 3 , wherein curing is by convection and said air temperature is measured as a mean exhaust temperature of a convection curing device.

26. A method as defined in claim 4 , wherein curing is by convection and said air temperature is measured as a mean exhaust temperature of a convection curing device.

27. A method as defined in claim 19 , wherein said tablet, when subjected to an indentation test, has at least one of (i) a cracking force of at

Assignees

• Purdue Pharma Lp
• Purdue Pharmaceuticals LP

Inventors

• Mckenna William H
• Mannion Richard O
• O'Donnell Edward P
• Huang Haiyong H

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P29/02

  without antiinflammatory effect · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61K9/1641 Primary

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers · CPC title